Back to today’s briefing

Story perspectives

Alzheimer's Drugs May Extend Independence but Carry Risks

2/16/2025

40 9

Summary

Story summary

A groundbreaking study reveals that Alzheimer’s drugs lecanemab and donanemab could prolong independent living by 8 to 39 months, depending on the severity of the disease. Despite their potential, these treatments come with significant side effects, high costs, and the need for regular infusions. Experts emphasize that while they slow decline, they do not cure the disease, urging patients to consult their doctors about their options.

1 of 1

Story summary

A groundbreaking study reveals that Alzheimer’s drugs lecanemab and donanemab could prolong independent living by 8 to 39 months, depending on the severity of the disease. Despite their potential, these treatments come with significant side effects, high costs, and the need for regular infusions. Experts emphasize that while they slow decline, they do not cure the disease, urging patients to consult their doctors about their options.